Registered entities
Nuclera Nucleics Ltd
Reg. No. 8663936United Kingdom
Innovation
91 patent families (23 granted) — focus: Chemistry & metallurgy, Operations & transport, Physics & computing; filing pace accelerating. Cited 1,519 times.
| Year | Filings |
|---|---|
| 2022 | 1 |
| 2023 | 21 |
| 2024 | 51 |
| 2025 | 50 |
| 2026 | 12 |
Social engagement
Social engagement: 25.8K social following, 10 posts in the last 12 months — below the industry typical range.
Investor mix
35 investors on record; lead investors include RT Partners, Elevage Medical Technologies, Elevage Medical Technologies.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 13 | 37% |
| Private equity | 3 | 9% |
| Bank & private debt | 1 | 3% |
| Other / undisclosed | 18 | 51% |
Hiring activity
Hires periodically
4 roles tracked across 3 of the last 12 months
21 Jun 2026 · Customer Service Specialist · Cambridge, England
7 Apr 2026 · Product Manager - Antibody Applications · Billerica
2 Dec 2025 · Production Technician · Billerica
Based on job postings tracked across public sources.
Recent activity
1 Jul 2026
Event
Webinar on integrating actionable screening data into your project planning
25 Jun 2026
Event
Drug DiscoveryTM benchmarking data proving translatability between Nuclera's eProtein DiscoveryTM system and larger scale E. coli production
24 Jun 2026
Event
Cell-free screening for AI antibody discovery pipelines